Corvus Pharmaceuticals, Inc. (CRVS)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Jan 21, 2025

$5.22

P/E Ratio

N/A

Market Cap

$335.42M

Jan 25, 2024Feb 29, 2024Apr 3, 2024May 6, 2024Jun 10, 2024Jul 16, 2024Aug 19, 2024Sep 24, 2024Oct 29, 2024Dec 3, 2024Jan 21, 2025$10.00$20.00
  • SEMR
Description

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in Burlingame, CA.

Metrics

Overview

  • HQBurlingame, CA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerCRVS
  • Price$5.22+4.19%

Trading Information

  • Market cap$335.42M
  • Float78.32%
  • Average Daily Volume (1m)748,986
  • Average Daily Volume (3m)1,159,746
  • EPS-$0.93

Company

  • RevenueN/A
  • Rev growth (1yr)N/A
  • Net income-$40.22M
  • Gross marginN/A
  • EBITDA marginN/A
  • EBITDA-$7.23M
  • EV$310.89M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B26.33
Documents